AbbVie Inc. (NYSE:ABBV) Q2 2025 Earnings Conference Call July 31, 2025 9:00 AM ET
Company Participants
Elizabeth Shea – Senior Vice President of Investor Relations
Jeffrey Ryan Stewart – Executive VP & Chief Commercial Officer
Robert A. Michael – CEO & Chairman of the Board
Roopal Thakkar – Executive VP of Research and Development & Chief Scientific Officer
Scott T. Reents – Executive VP & CFO
Conference Call Participants
Asad Haider – Goldman Sachs Group, Inc.
Carter Lewis Gould – Cantor Fitzgerald & Co.
Christopher Thomas Schott – JPMorgan Chase & Co
David Reed Risinger – Leerink Partners LLC
Gary Jay Nachman – Raymond James & Associates, Inc.
Mohit Bansal – Wells Fargo Securities, LLC
Stephen Michael Scala – TD Cowen
Terence C. Flynn – Morgan Stanley
Timothy Minton Anderson – BofA Securities
Vamil Kishore Divan – Guggenheim Securities, LLC
Operator
Good morning, and thank you for standing by. Welcome to AbbVie’s Second Quarter 2025 Earnings Conference Call. [Operator Instructions] Today’s call is also being recorded. If you have any objections, you may disconnect at this time.
I would now like to introduce Ms. Liz Shea, Senior Vice President, Investor Relations. Ma’am, you may begin.
Elizabeth Shea
Thank you. Good morning, and thanks for joining us. Also on the call with me today are Rob Michael, Chairman and Chief Executive Officer; Jeff Stewart, Executive Vice President, Chief Commercial Officer; Roopal Thakkar, Executive Vice President, Research and Development, Chief Scientific Officer; and Scott Reents, Executive Vice President, Chief Financial Officer.
Before we get started, I’ll note that some statements we make today may be considered forward-looking statements based on our current expectations. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in our forward-looking statements. Additional information about these risks
#AbbVie #ABBV #Earnings #Call #Transcript